The fungal toxin fusicoccin induces plant wilting by affecting ion transport across the plasma membrane of plant cell. The activity of this toxin is so far unknown in humans. In the present study we show that fusicoccin is able to affect the platelet aggregation process. The toxin associates with platelet intracellular binding sites and induces aggregation in platelet-rich plasma in a dosedependent manner. We identified the adhesion receptor glycoprotein Ib-IX-V as fusicoccin target. The toxin promotes the binding of the regulatory 14-3-3 proteins to glycoprotein Ibα and hampers that to glycoprotein Ibβ subunit. As a result, platelet adhesion to von Willebrand factor is stimulated, leading to platelet spreading and integrin αIIbβ3 activation. We anticipate the present study to be a starting point for future therapeutic use of fusicoccin in genetic bleeding diseases characterized by qualitative or quantitative abnormalities of the platelet membrane-adhesion receptors. Furthermore, the present study also sets the stage for future work to determine the potential pharmacological application of fusicoccin as a drug directed to other 14-3-3-target complexes.
INTRODUCTION

FC (fusicoccin) (
), a diterpene glucoside produced by fungus Phomopsis amygdali, is the causative agent in the wilting of peach and almond trees infected by the pathogen [1] . Despite the fact that P. amygdali is host-specific, FC is active on any higher plant, and its effects have been attributed to its ability to stimulate the plasma membrane H + -ATPase, a key enzyme in the control of ion transport across the plasma membrane of plant cells. FC promotes the permanent association of regulatory 14-3-3 proteins with the proton pump cytosolic C-terminal domain [2, 3] , which plays an autoinhibitory function, thereby leading to its displacement and enzyme activation [4] .
14-3-3 is a family of highly homologous proteins that form both homo-and hetero-dimers. This family consists of two distinct gene products in yeast, seven in human cells and 12 in Arabidopsis thaliana [5, 6] .
14-3-3 proteins are involved in the co-ordination of a diverse array of cellular processes, such as cell-cycle progression, apoptosis, protein trafficking, signal transduction and gene expression [5, 6 ]. 14-3-3 proteins exert their effects through binding to a variety of protein targets in a sequence-specific and phosphorylationdependent manner. The analysis of 14-3-3 targets and structural studies have initially established two consensus binding motifs, RSX(pS/pT)XP and RXY/FX(pS/pT)XP (where X is any amino acid and pS/pT represents phosphorylated serine or threonine), which have been defined as mode I and II recognition motifs respectively [7] [8] [9] . These motifs are recognized by a conserved amphipathic groove present in each 14-3-3 monomer. The vast majority of binding sites matches either mode I or II consensus binding motifs, but unrelated binding sequences have also been identified. A limited number of targets binds 14-3-3 through a C-terminal binding site. Although structurally unrelated, these Cterminal binding motifs have been proposed as mode III [10] . The H + -ATPase binds 14-3-3 proteins via a mode III motif (XXYpTV), located at the very end of the C-terminus [3] .
FC action has been clarified at the molecular level: the crystal structure of the ternary complex between 14-3-3, a phosphorylated pentapeptide of H + -ATPase and FC revealed that the toxin is accommodated into a cavity in the 14-3-3 groove and strictly contacts the C-terminal residue of the peptide, leading to mutual stabilization of both ligands [11] .
Although a previous study has show its effects on an animal system [12] , the activity of this toxin is completely unknown in humans where FC-binding proteins have not yet been identified. According to the FC mechanism-of-action in plants, potential targets of the toxin are proteins which bind 14-3-3 via a C-terminal motif, even though FC's ability to regulate 14-3-3 association with targets with internal motifs cannot be excluded.
In humans, a well-characterized 14-3-3 target containing a mode III motif is GPIbα [the Ibα subunit of GPIb-IX-V (glycoprotein Ib-IX-V)] [13] , a membrane protein complex expressed on the platelet plasma membrane which mediates the initial adhesion of circulating platelets to vessel wall matrix under high-shear conditions [14] . All of the six 14-3-3 isoforms expressed in platelets bind to GPIb-IX-V [15] . In particular, binding of 14-3-3ζ to the C-terminal sequence RYSGHpSL -COOH of GPIbα is essential for the ability of GPIb-IX-V to bind subendothelial vWF (von Willebrand factor) [16] .
In the present study we explored the possibility that FC action could not be restricted to the H + -ATPase-14-3-3 interaction, but it may be extended to other 14-3-3 targets sharing with the H + -ATPase the mode III-binding motif. Therefore we investigated Figure 1 Chemical structure of the fungal toxin fusicoccin the effect FC of on the interaction between 14-3-3 proteins and GPIbα, and the functional consequence of FC action on the platelet aggregation process.
EXPERIMENTAL
Chemicals
FC was prepared as described by Ballio et al. [17] . [ 3 H]FC (specific activity 8.75 Ci/mmol) was prepared as described by Ballio et al. [18] . The aglycone of FC was prepared as described by Ballio et al. [19] . BSA-FC (BSA-dideacetylFC; FC/BSA ratio 10:1) was prepared according to Aducci et al. [20] .
The biotinylated peptides H + -ATPase (LKGLDIDTIQQNYp-TV -COOH ), Raf-1 (EGSLSQRQRSTpSTPN -COOH ), Raf-1 PN (EGSLSQRQRSTpST -COOH ), GPIbα term (DLLSTVSIRYSGHp-SL -COOH ), and the corresponding unphosphorylated peptides, were synthesized by Neosystem. GPIbα int (VPRAWLLFLRGpSL-PT -COOH ), GPIbβ (Ibβ subunit of GPIb-IX-V) (RARARAAARLpSLTDP -COOH ), the corresponding unphosphorylated peptides and MPαC myristoylated peptide (C 13 H 27 CONHSIRYSGHpSL -COOH ), were synthesized by JPT Peptide Technologies. Human vWF was purchased from Haematologic Technologies. IgG from goat serum, anti-GPIbα (CD42b-C20 and CD42b-N19) and anti-GPIbβ (CD42c-C20) antibodies were from Santa Cruz Biotechnology. RGDS peptide, ristocetin, PKA (protein kinase A) and the other chemicals were from Sigma-Aldrich.
Binding of 14-3-3ζ to phosphopeptides
Biotinylated peptides (0.5 nmol) were immobilized on to 20 μl of streptavidin-agarose magnetic beads (Sigma-Aldrich). Beads were incubated at 25
• C for 60 min at 25
• C in 50 μl of buffer HT [25 mM Hepes-OH, 75 mM KCl, 5 mM MgCl 2 , 1 mM DTT (dithiothreitol), 0.1 mM EDTA and 0.04 % Tween 20 (pH 7.5)] containing 10 μM 32 P-labelled 14-3-3ζ in the presence of various FC concentrations. Bead-bound radioactivity was measured in a liquid-scintillation β-counter. Dissociation constants (K d ) were estimated with homologous competitive binding experiments, using GraphPad Prism5 (GraphPad Software) for data analysis.
Platelet preparation
Washed platelets were prepared from PRP (platelet-rich plasma) obtained from healthy donors who had not taken medication for at least 9 days before bleeding. PRP was obtained by differential centrifugation at 1100 g for 5 min as described by Jin et al. [21] . The research has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. Blood donors gave informed consent to the work.
Expression of 14-3-3ζ
Human 14-3-3ζ was expressed in Escherichia coli as a fusion protein with GST (glutathione transferase) using pGEX-2TK vector, following the procedure described by Sottocornola et al. [22] .
Immunoprecipitation and overlay assay
Immunoprecipitation was performed using the anti-GPIbα antibody CD42b-C20 and the Protein G immunoprecipitation kit IP50 (Sigma-Aldrich) according to the manufacturer's instructions. SDS/PAGE was performed as described by Laemmli [23] . Non-reducing gel electrophoresis was performed omitting 2-mercaptoethanol from the loading buffer. Overlay experiments were performed as described by Camoni et al. [24] using 0.3 μM 32 P-labelled 14-3-3ζ (8.3 kBq/ml) as a probe and, where indicated, 40 μM FC. Densitometric analysis was performed using the ImageJ image-processing program [25] , developed by the National Institutes of Health and freely available at http://rsbweb.nih.gov/ij. Densitometric values are expressed as a percentage of the maximum integrated densitometric value (the product of the area and mean grey value).
Binding of FC to isolated platelets
To measure FC-binding activity of platelets, 30 μl of platelet suspension (2.0 × 10 8 /ml) were incubated for 30 min at 37
• C with 1 μM [ 3 H]FC in 100 μl of PBS containing 5 mM MgCl 2 , in the presence of different concentrations of FC or FC derivatives. Platelets were centrifuged at 2000 g and, after the addition of 500 μl of 7% perchloric acid, the radioactivity was measured in a scintillation β-counter. Dissociation constant (K d ) and maximal binding capacity (B max ) were estimated with homologous competitive-binding experiments, using GraphPad Prism5 (GraphPad Software) for data analysis.
Platelet adhesion
Platelet adhesion to immobilized vWF was performed in polystyrene microtitre plate wells as described by Lu et al. [26] , using vWF concentrations ranging from 0.1 to 20 μg/ml. Control experiments were carried out replacing vWF with BSA. Where indicated, platelets were pre-incubated for 10 min with 40 μM FC or 2 μg/ml anti-GPIbα (CD42b-N19) antibody. The number of vWF-bound platelets was calculated by measurement of endogenous acid phosphatase as described by Lu et al. [26] using an automated plate reader.
Platelet aggregation
PRPs were pre-incubated at 37
• C with different FC concentrations and, when indicated, 1 mg/ml ristocetin, 0.75 mM RGDS or 0.1 mM MPαC was added. Aggregation was measured using a turbidometric platelet aggregometer Chrono-log 560 CA (Chrono-log Corporation). PRP (500 μl) was placed in a cuvette at 37
• C under continuous stirring at 1000 rev./min. Aggregation was expressed as a percentage of the change in light transmission, with the values of the blank sample [PPP (platelet-poor plasma)] and PRP set at 100 % and 0 % respectively.
Statistical analysis
Statistical significance was assessed by unpaired Student's t test. All values are expressed as means + − S.E.M.
RESULTS
FC action on mode I and mode III targets
In order to ascertain the potential ability of FC to be a general modulator of 14-3-3 interactions with client proteins, we analysed the structural requisites of 14-3-3 targets to allow the FC regulatory function. To this purpose, the effect of FC on the 14-3-3 interaction with different phosphopeptides, reproducing internal and C-terminal binding sequences, was tested. For these studies, the human 14-3-3ζ isoform was used.
H + -ATPase peptide mimics the C-terminal mode IIIrecognition site of the plasma membrane H + -ATPase. As expected, 10 and 100 μM FC significantly stimulated the association of 14-3-3ζ (Figure 2A) .
Raf-1 peptide mimics the mode I-recognition site surrounding Ser 259 of Raf-1 kinase, whereas the shorter Raf-1 PN peptide, which reproduces the first 13 amino acids of Raf-1 peptide, has the phospho-serine residue as the penultimate amino acid and therefore represents a mode III-binding sequence. As shown in Figure 2 (A), 14-3-3 binding to Raf-1 peptide is unaffected by 10 μM FC. This result is in agreement with structural data showing that the amphipathic groove of 14-3-3 is totally occupied by mode I peptide, thus not allowing FC binding [11] . 14-3-3 binding to Raf-1 peptide is instead significantly inhibited at higher FC concentrations (100 μM). It is known that FC can directly bind 14-3-3 proteins, although at low affinity (K d = 66 μM) [11] . At high FC concentrations, the 14-3-3-binding groove involved in peptide binding is occupied by the toxin and therefore peptide association is hampered.
Raf-1 PN peptide does not bind 14-3-3ζ , but FC addition can significantly promote the interaction. This result reveals that the mode III Raf-1 PN peptide allows FC to be accommodated into the 14-3-3-binding groove ( Figure 2B ), thus leading to the formation of a ternary complex. Hence, this result demonstrates that FC action can be more generally extended to 14-3-3 targets with a C-terminal-recognition motif.
GPIb-IX-V is formed by four different transmembrane proteins: GPIbβ, which consists of disulfide-linked GPIbα and GPIbβ, GPIX and GPV. In this complex, three 14-3-3-binding sites have been proposed: the mode III motif -SGHpS 609 L -COOH , located at the C-terminus of GPIbα, and the internal motifs -LRGpS 557 LPT and -ARLpS 166 LTDP, located on the cytoplasmic region of GPIbα and GIbβ respectively [16] .
To ascertain whether the interaction between 14-3-3 proteins and the mode III-binding motif of GPIbα can be stabilized by FC, in a similar manner to the interaction with the H + -ATPase, an in vitro assay using a synthetic phosphopeptide reproducing the 14-3-3-binding sequence of GPIbα was carried out. Interestingly, 14-3-3 binding to GPIbα term phosphopeptide is strongly stimulated by both 10 and 100 μM FC (Figure 2A ). In this interaction a K d of 1.33 + − 0.07 μM for 14-3-3 in the presence of 10 μM FC and a K d of 13.61 + − 0.33 μM in the absence of the toxin were calculated from homologous competitive binding curves (results not shown). Remarkably, FC produces a 10-fold decrease in K d , according to the effect observed in the H + -ATPase-14-3-3 interaction [3, 11] .
The FC effect on the 14-3-3 interaction was also studied with peptides reproducing the internal motifs of GPIbα and GPIbβ. Surprisingly, GPIbα int peptide does not bind 14-3-3ζ either in the absence or in the presence of FC. On the other hand, the effect 32 P]14-3-3ζ in the absence (white bars) or in the presence of 10 μM (grey bars) or 100 μM (black bars) FC. After washing, resin-associated radioactivity was measured. *P < 0.01 measured by Student's t test (n = 6). The experiment was carried out also using the corresponding unphosphorylated peptides and no binding to of FC on GPIbβ peptide resembles that obtained with mode I Raf-1 peptide: GPIbβ peptide binds 14-3-3ζ and the interaction is significantly hampered by 100 μM FC.
The effect of FC on the 14-3-3 interaction with GPIbα term and GPIbβ phosphopeptides was further investigated using different FC concentrations, ranging from 0.1 to 150 μM. As shown in GPIb was immunopurified from platelet protein extract using an anti-GPIbα polyclonal antibody and subjected to SDS/PAGE (lanes anti-GPIbα) on 7% (A) or 12% (B) gels. After transfer on to a nitrocellulose membrane, the protein was incubated with 0.3 μM the mode I GPIbβ peptide is statistically significant from FC concentrations higher than 50 μM (P < 0.01 by Student's t test). These results propose the potential ability of FC to affect 14-3-3 binding to GPIb-IX-V when administered in the micromolar range, thus altering glycoprotein biochemical properties.
FC effect on the 14-3-3 interaction with GPIbα and GPIbβ
In order to verify whether FC can affect the interaction between GPIb and 14-3-3ζ , the protein was purified from isolated platelets by immunoprecipitation using the polyclonal anti-GPIbα antibody and the interaction was tested using an overlay assay. As shown in Figure 3 (A) (upper panels) 14-3-3ζ recognizes the bands corresponding to GPIbα (reducing conditions, lane R.) and GPIb complex (non-reducing conditions, lane N.R.), Interestingly, FC greatly increases the 14-3-3 association with the proteins, with a more pronounced effect observed with the GPIbα subunit.
The interaction of 14-3-3 with the β-subunit of GPIb was also studied. As shown in Figure 3 (B) (upper panels) 14-3-3ζ associates with a band corresponding to GPIbβ which dissociates from the α-subunit under reducing conditions. Notably, a reduced interaction was observed in the presence of the toxin. The opposite effects of FC on the 14-3-3ζ interaction with GPIbα and GPIbβ in the overlay assay resemble the effects of the toxin on 14-3-3 binding to GPIbα term and GPIbβ phosphopeptides (Figure 2A ), and therefore are very likely to be ascribable to the presence of a 14-3-3 mode III motif in GPIbα and a mode I-like internal motif in GPIbβ.
These results, summarized in Figure 3 (C), propose the potential ability of FC to bind platelet in vivo and consequently to affect the physiological process where GPIb-IX-V takes part. This hypothesis requires the ability of FC to cross the platelet plasma membrane. As shown in Figure 3(D This finding reveals the ability of FC to gain access to the platelet cytosol and thus to associate with intracellular binding sites. The K d , as estimated by homologous competition curve fitting (results not shown), is 16.1 + − 0.59 μM. This value is fully consistent with FC activity in the 14-3-3-GPIb peptide-binding assay, thus further suggesting a capability of FC to affect GPIb-IX-V-mediated functional processes. Maximal FC binding capacity (B max ) is (2.0 + − 0.2) × 10 5 sites/platelet. This value is 4-fold higher than the presumed number of GPIbα molecules/platelet, which is approximately 50 000 [14] , thus suggesting that other platelet proteins are also responsible for FC binding. Among these, 14-3-3 proteins can significantly contribute to total FC binding, since it is known their ability to directly bind FC [11] .
FC stimulates platelet adhesion to vWF
Under high-shear rate flow conditions, such as in arteries and capillaries, platelet adhesion is mediated by the interaction between subendothelial vWF and its receptor GPIb-IX-V [14] . Platelet binding activates intracellular signalling events leading to activation of the ligand-binding function of the integrin αIIbβ3 and the consequent platelet spreading and aggregation. Since 14-3-3ζ association with the GPIbα subunit is essential for the vWFbinding activity of GPIb-IX-V, it is conceivable that FC-induced stabilization of 14-3-3 binding could promote platelet adhesion to vWF.
The effect of FC on adhesion was therefore studied by measuring purified platelet binding to different concentrations of immobilized vWF. As reported in Figure 4 (A), 40 μM FC strongly stimulates platelet adhesion to vWF when both resting ( − ADP) or activated ( + ADP) platelets were used. The observed stimulatory effect of FC, even under maximal activation conditions ( + ADP), indicates the ability of the toxin to increase the number of platelets bound to vWF via GPIbα, resulting in platelet spreading and integrin activation. Moreover, the stimulatory effect of FC on adhesion is considerably higher when lower concentrations of vWF were used ( Figure 4B ). Thus this finding provides a quantitative correlation between the FC effect and the functional response mediated by the GPIb-IX-V receptor.
In order to further confirm the involvement of GPIb-IX-V in the FC-mediated stimulation of adhesion, the effect of a polyclonal antibody, recognizing an extracellular epitope of GPIbα, was tested. As shown in Figure 4 (C), the antibody partially inhibits adhesion of resting platelets. Instead, adhesion of ADP-activated platelets, which is mainly mediated by binding of integrin αIIbβ3 to vWF [27, 28] , is unaffected. Interestingly, an anti-GPIbα antibody partly hampers FC-mediated platelet adhesion to vWF both when resting and when activated platelets were used, thus demonstrating that the effect of FC involves stimulation of GPIbα binding to vWF.
FC induces platelet aggregation
The effect of different FC concentrations on platelet aggregation was tested in PRP using an optical aggregometer. As shown in Figure 5 (A), FC triggers platelet aggregation. The effect is detectable at 10 μM and reaches its maximum at 40 μM FC. The slight and dose-dependent aggregation induced by FC does not resemble the well-known effect induced by ristocetin, which causes massive platelet agglutination [29] . RGDS peptide, which inhibits aggregation by blocking fibrinogen binding to integrin αIIbβ3 [30] , completely abolishes FC-induced aggregation ( Figure 5B), thus demonstrating the involvement of integrin αIIbβ3 activation in this process. The full inhibitory effect of RGDS peptide also indicates that in PRP the toxin does not promote a detectable platelet agglutination resulting from the interaction of GPIb-IX-V and blood plasma vWF.
The involvement of 14-3-3 proteins in FC-induced platelet aggregation was demonstrated by testing the myristoylated phosphopeptide MPαC, which reproduces the 14-3-3-binding site of GPIbα. It is well established that this peptide is able to cross the platelet membrane and to inhibit platelet aggregation by competition with GPIb-IX-V for 14-3-3 binding [16] . As shown in Figure 5 (C), MPαC peptide completely abolished the aggregation induced by the toxin, demonstrating that 14-3-3 proteins are critical in the FC-promoted process. Addition of 1.0 mg/ml ristocetin induces a faster aggregation in FC-activated platelets, thus revealing an additive effect of FC and ristocetin. As already shown by Dai et al. [16] , the ristocetin effect is strongly hampered in platelets treated with 0.1 mM MPαC peptide. Notably, the FC effect in MPαC-treated platelets is also completely inhibited after ristocetin addition, confirming the strict requirement of 14-3-3 proteins for the effect of the toxin on platelet aggregation.
The effect on platelet aggregation of simultaneous addition of FC and ristocetin was also tested. As shown in Figure 5 (D), no effect of FC on ristocetin-induced aggregation was detectable in the early phase of aggregation, whereas only a slight effect can be measured after approximately 3 min, confirming that the aggregation process promoted by the toxin is slower than that induced by ristocetin.
DISCUSSION
The discovery of small molecules capable of selectively modulating 14-3-3 binding with client protein represents a c The Authors Journal compilation c 2011 Biochemical Society promising strategy to control physiological processes where 14-3-3 proteins play a role. In the present study we show that FC, a cell-permeant fungal toxin whose activity has been so far deeply investigated only in plants, can also affect an essential physiological process in humans. We demonstrated that platelets possess specific intracellular FC-binding sites, and we identified the platelet-adhesion receptor GPIb-IX-V as an FC target. The toxin stabilizes the 14-3-3 interaction with the Ibα subunit, whereas association with Ibβ subunit is hampered. Results obtained also suggest the rationale for the FC effect. In fact, the presence of a C-terminal 14-3-3-binding motif in GPIbα allows insertion of FC in the 14-3-3-binding groove. As a result, the toxin stabilizes the association of GPIbα with 14-3-3, in a similar manner to the H + -ATPase-14-3-3 interaction ( Figure 2B ). The FC-binding pocket is instead occupied in the 14-3-3-GPIbβ complex, and consequently the toxin cannot bind to the complex. Since FC can form a low-affinity binary complex with 14-3-3, a high FC concentration can inhibit 14-3-3 binding to GPIbβ by competition.
It is well established that 14-3-3 binding to the Ibα subunit and dissociation from the Ibβ subunit contribute to activate vWFbinding functions of GPIb-IX-V [16] . Accordingly, we found that FC is able to stimulate GPIbα-dependent platelet association with vWF and to promote platelet aggregation via integrin αIIbβ3 activation. The effect of FC on platelet aggregation is partial and dose-dependent, thus suggesting the ability of toxin to partly activate an intracellular pathway. We also found that the MPαC peptide, a cell-permeant competitor of 14-3-3 intracellular targets, completely abolishes FC-induced aggregation. Although we cannot rule out the possibility that the FC effect on aggregation involves other 14-3-3 client proteins, our results strongly indicate that the GPIb-IX-V complex is a fundamental target of FC action.
The elucidation of the molecular basis of FC-induced platelet aggregation opens new opportunities for a therapeutic use of the toxin. Possible pharmaceutical applications are genetic bleeding disorders, such as Bernard-Soulier syndrome and Glanzmann's thrombasthenia, characterized by qualitative or quantitative abnormalities of the platelet membrane proteins GPIb-IX-V and integrin αIIbβ3 respectively [31] . Moreover, since the interaction between vWF and GPIb-IX-V is of pivotal importance in the initial adhesion of platelets to the subendothelium under highshear conditions, such as those found in atherosclerotic vessels, inhibition of GPIb-IX-V activity is one of the major targets of anti-thrombotic drug research [32] . The present study sets the stage for future work to design FC-derived molecules which could specifically reduce aggregation by inhibiting 14-3-3 binding to GPIbα.
Moreover, a number of 14-3-3 clients with mode III-binding motifs have been identified in mammals [10] . The results of the present study suggest that 14-3-3 association with these targets could be stabilized by FC, in a similar manner to the 14-3-3-GPIbα interaction. Future work will address the structural prerequisites for the action of FC and the potential pharmacological application of FC as a drug directed to 14-3-3-target complexes.
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